182,784 Shares in Pfizer Inc. (NYSE:PFE) Acquired by Chase Investment Counsel Corp

Chase Investment Counsel Corp purchased a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the third quarter, according to its most recent 13F filing with the SEC. The fund purchased 182,784 shares of the biopharmaceutical company's stock, valued at approximately $5,289,000. Pfizer makes up 1.8% of Chase Investment Counsel Corp's investment portfolio, making the stock its 22nd largest position.

Several other institutional investors have also recently made changes to their positions in PFE. Empower Advisory Group LLC boosted its stake in Pfizer by 4.0% during the third quarter. Empower Advisory Group LLC now owns 4,029,978 shares of the biopharmaceutical company's stock valued at $116,628,000 after buying an additional 153,573 shares during the period. Barnett & Company Inc. boosted its position in shares of Pfizer by 5.9% during the 3rd quarter. Barnett & Company Inc. now owns 213,625 shares of the biopharmaceutical company's stock valued at $6,182,000 after acquiring an additional 11,970 shares during the last quarter. First Heartland Consultants Inc. grew its holdings in shares of Pfizer by 2.9% during the third quarter. First Heartland Consultants Inc. now owns 15,860 shares of the biopharmaceutical company's stock worth $459,000 after purchasing an additional 449 shares in the last quarter. Missouri Trust & Investment Co increased its position in shares of Pfizer by 8.4% in the third quarter. Missouri Trust & Investment Co now owns 49,956 shares of the biopharmaceutical company's stock worth $1,446,000 after purchasing an additional 3,885 shares during the last quarter. Finally, Aigen Investment Management LP bought a new stake in Pfizer during the third quarter valued at approximately $1,087,000. Institutional investors own 68.36% of the company's stock.

Insider Buying and Selling

In other news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction on Wednesday, October 30th. The stock was acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the purchase, the director now owns 10,000 shares in the company, valued at $282,400. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is currently owned by company insiders.

Pfizer Stock Up 1.9 %

NYSE PFE traded up $0.49 during trading hours on Wednesday, reaching $26.68. 29,541,604 shares of the company's stock traded hands, compared to its average volume of 37,693,445. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a 50-day simple moving average of $28.80 and a 200 day simple moving average of $28.68. The firm has a market cap of $151.20 billion, a PE ratio of 35.54, a PEG ratio of 0.83 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. During the same period last year, the business earned ($0.17) earnings per share. The business's revenue was up 31.2% on a year-over-year basis. Sell-side analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 6.30%. Pfizer's payout ratio is presently 227.03%.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Sanford C. Bernstein initiated coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a "market perform" rating and a $32.00 price objective on the stock. Daiwa Capital Markets upgraded Pfizer from a "neutral" rating to an "outperform" rating and raised their price target for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Barclays lifted their price target on Pfizer from $30.00 to $32.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 31st. Cantor Fitzgerald reissued an "overweight" rating and set a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. Finally, UBS Group boosted their target price on Pfizer from $30.00 to $31.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, five have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $33.58.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.